(via Thread by @Daniel_E_Park on Thread Reader App – Thread Reader App)
Excellent broad cross neutralization to variants with the upcoming JN.1 Novavax COVID vaccine, including some of the best responses to variants that are likely to be dominant this late fall and early winter
https://novavax.widen.net/s/zg79lxwknx/2024-q2-earnings-presentation
The latest CDC nowcast shows a rapid rise in KP3.1.1, which is the variant with best response to the NVX JN.1 vaccine. Others variants to keep an eye on include LB.1 (a direct JN.1 descendant) and LP.1 (KP1.1 descendant) https://covid.cdc.gov/covid-data-tracker/#variant-proportions
This follows an expected decline in KP.2 over the last few weeks, which is one reason why VRBPAC recommended not chasing this branch (KP.2 variant) but to target the trunk (JN.1).
Ultimately as the antigenic distance is very close for all major circulating variants, all vaccine options should be very good, and provide good protection against infection and severe disease (even when compared with infection-acquired/natural immunity).



















